These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10583524)

  • 1. Financial aspects of haemophilia care in Puerto Rico and other Latin American countries.
    Santiago-Borrero PJ; Ortiz I; Rivera-Caragol E; Maldonado NI
    Haemophilia; 1999 Nov; 5(6):386-91. PubMed ID: 10583524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Musculoskeletal evaluation in severe haemophilia A patients from Latin America.
    Ozelo MC; Villaça PR; Pérez-Bianco R; Candela M; Garcia-Chavez J; Moreno-Rodriguez B; Rodrigues MB; Rodriguez-Grecco I; Solano MH; Chumpitaz G; Morales-Gana MM; Ruiz-Sáez A
    Haemophilia; 2014 Jan; 20(1):e63-70. PubMed ID: 24354487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization among haemophilia A patients in the United States.
    Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
    Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost of health care in children with haemophilia].
    González-Figueroa M; Canales-Muñoz JL; Aguayo-Alcaraz G; Zamora-Vázquez G
    Rev Med Inst Mex Seguro Soc; 2010; 48(2):199-204. PubMed ID: 20929625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
    Globe DR; Curtis RG; Koerper MA;
    Haemophilia; 2004 Mar; 10 Suppl 1():63-70. PubMed ID: 14987251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
    Lorenzoni V; Triulzi I; Turchetti G
    BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
    Ullman M; Hoots WK
    Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financing the rising cost of haemophilia care at a large comprehensive care centre.
    Miners AH; Sabin CA; Stevens AJ; Tolley KH; Lee CA
    J R Coll Physicians Lond; 1997; 31(6):640-4. PubMed ID: 9409497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemophilia care in Latin America: Assessment and perspectives.
    Boadas A; Ozelo MC; Solano M; Berges A; Ruiz-Saez A; Linares A; Lamas JL; Aparicio R; Aversa L; Baques A; Estrada A; Herrejon M; Mancia A; Nieves-Paulino R; Pinto I; Prezoti A; Soto V; Ugalde D
    Haemophilia; 2018 Nov; 24(6):e395-e401. PubMed ID: 30144214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A synopsis of current haemophilia care in Hong Kong.
    Au WY; Lee V; Kho B; Ling AS; Chan D; Chan EY; Chan GC; Cheung WW; Lau CW; Lee CY; Li RC; Li CK; Lin SY; Mak V; Sun L; Wong KH; Wong R; Yau J; Yuen HL
    Hong Kong Med J; 2011 Jun; 17(3):189-94. PubMed ID: 21636866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of haemophilia in Sweden.
    Nilsson IM
    Thromb Haemost; 1976 Jun; 35(3):510-21. PubMed ID: 989956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients].
    Berger K; Schopohl D; Eheberg D; Oldenburg J; Tiede A; Schramm W
    Hamostaseologie; 2014; 34(4):291-300. PubMed ID: 25370177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemophilia A and the blood transfusion service: a Scottish study.
    Cash JD; Spencely M
    Br Med J; 1976 Sep; 2(6037):682-4. PubMed ID: 974537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The history of haemophilia - a short review.
    Schramm W
    Thromb Res; 2014 Nov; 134 Suppl 1():S4-9. PubMed ID: 24513149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemophilia care in Europe: the ESCHQoL study.
    Schramm W; Gringeri A; Ljung R; Berger K; Crispin A; Bullinger M; Giangrande PL; Von Mackensen S; Mantovani LG; Nemes L; Serban M;
    Haemophilia; 2012 Sep; 18(5):729-37. PubMed ID: 22639833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prenatal care in Latin America].
    Buekens P; Hernández P; Infante C
    Salud Publica Mex; 1990; 32(6):673-84. PubMed ID: 2089644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic issues in European self-sufficiency.
    Szucs TD
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S51-5. PubMed ID: 7795140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.